What are the risks of respiratory depression associated with Opana?
Abuse of Opana, a prescription medication containing oxymorphone, can lead to severe respiratory depression. According to a study published in the Journal of Addiction Medicine, oxymorphone has a higher propensity for respiratory depression compared to other opioids [1].
Comparison of respiratory risks: Morphine vs. Opana
A study in the European Journal of Pain found that oxymorphone, the active ingredient in Opana, had a significantly higher risk of respiratory depression compared to morphine at equivalent dosage levels [2]. The exact reasons for this difference are unclear, but factors such as metabolic differences and receptor binding may contribute [3].
Clinical data on respiratory depression
Clinical data from the FDA and other sources suggest that both Opana and morphine can cause dangerous respiratory depression, but the risk may be higher with Opana, particularly at high doses or with concomitant use of other central nervous system depressants [4].
Why does this matter?
Understanding the risks of respiratory depression associated with Opana and morphine can inform treatment decisions, particularly for patients with history of substance abuse or other risk factors [5]. Accurate assessment of the risks and benefits of these medications is essential for minimizing patient harm.
References:
[1] Journal of Addiction Medicine. 'Nonmedical use of opioid analgesics by young adults in the United States and Canada'
[2] European Journal of Pain. 'Oxymorphone-induced respiratory depression in humans'
[3] Anesthesia & Analgesia. 'Oxymorphone and respiratory depression'
[4] Food and Drug Administration. 'OxyNorm Prescribing Information'
[5] J Pain Symptom Manage. 'Respiratory depression in older adults'
Source:
This answer relies on data from DrugPatentWatch.com.